Skip to main content

Table 3 Clinical findings of CML patients non-responsive to imatinib therapy and potential biomarkers at the molecular response

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Total No Age (year) Duration on TKIs (month) IRIS molecular response (BCR-ABL1ISa) Relative expressionb of hsa-miR-181a-5p (fold regulation) (collectively = 2.33 down-regulation) Relative expressionb of hsa-miR-182-5p (fold regulation) (collectively = 2.08 up-regulation) Relative expressionb of hsa-miR-26a-5p (fold regulation) (collectively = 2.39 up-regulation)
7 20–64 13–142 >  10% − 41.3405 to 2.0286 −2.3320 to 9.5690 −2.9519 to 12.6264
5 43–64 47–92 ≤ 10% −6.5409 to − 1.3561 −1.5069 to 1.9297 − 1.4556 to 2.6728
6 22–49 11–58 ≤ 1% −4.3154 to −1.0566 − 1.1031 to 2.8252 − 1.5819 to 3.2229
5 21–64 35–131 ≤ 0.1% −4.4367 to − 1.3009 −1.1108 to 4.3120 − 1.3581 to 11.0684
2 36–61 29–109 MR4 −1.9178 and 1.0501 4.0233 and 5.8904 5.8497 and 7.4559
2 42–60 26–75 MR4.5 −2.3776 and 1.1333 1.1474 and 7.1027 1.1083 and 2.7102
1 64 65 undetermined 1.5916 8.1589 13.9131
28 20-64c
(46.04 ± 14.25)d
11-142c
(61.86 ± 36.33)d
    
  1. aInternational Scale
  2. bcomparing to control group
  3. cRange
  4. dmean ± sd